UroAlert - GU Oncology Weekly

March 05, 2026

Videos

Peer-to-Peer Clinical Conversations

Developing a Patient-Centered Decision Aid for Urinary Diversion Choices in Bladder Cancer - Divya Ajay

Divya Ajay discusses a patient-centered decision aid for urinary diversion selection developed through BCAN's Young Investigator Award.

Non-Urothelial Recurrence Patterns After Nephroureterectomy for Upper Tract Cancer - Andrew Katims

Andrew Katims

Sam Chang speaks with Andrew Katims about a multi-institution study examining non-urothelial recurrences after nephroureterectomy for upper tract urothelial carcinoma.

Beyond the Abstracts

Bacillus Calmette-Guérin Plus Mitomycin versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) - Beyond the Abstract

Kidney-Sparing Treatments for Local Recurrence in Renal Cell Tumours after Partial Nephrectomy or Focal Therapy: A Systematic Review - Beyond the Abstract

Conference Coverage

ASCO GU 2026: STRIKE! (Alliance A032201): Short Term Intensified Pembrolizumab and Tivozanib for High-Risk RCC

ASCO GU 2026: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable RCC: Preliminary Results from the MONSTAR-SCREEN-3 Study

ASCO GU 2026: Topline Results from BOND-003 Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive NMIBC

ASCO GU 2026: ctDNA-Guided Adjuvant Atezolizumab in MIBC: Exploratory Analysis of ctDNA Dynamics in the IMvigor011 Trial

ASCO GU 2026: ECOG ACRIN EA8291 Cohort C: A Phase II Trial of Neoadjuvant Gemcitabine/Durvalumab in Patients with High Grade UTUC Ineligible for Cisplatin-Based Chemotherapy

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.

Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.

Computational pathology in bladder cancer: A scoping review.

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.

External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study.

Navigating bladder preservation in Bacillus Calmette-Guérin-unresponsive disease: how much risk is too much?

Penile & Urethral Cancers

Low yield of pathological lymph node metastasis among patients with invasive penile squamous cell carcinoma in the context of high HIV burden: evidence from a prospective cohort study in Zambia.

Renal Cancer

Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.

Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.

Preoperative predictors of adverse pathology and recurrence-free survival for patients with renal masses.

Renal Cell Carcinoma: Characteristics of Patients, Treatment, and Disease Progression Based on Real-World Data From a Cancer Center in Medellín, Colombia.

KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model.

Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician Priorities.

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.

Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy.

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium.

Prostate Cancer

Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer.

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

MRI for Active Surveillance in Prostate Cancer: How I Do It.

Impact of smoking on health-related quality-of-life outcomes in prostate cancer survivors.

Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration.

Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort.

Real-world functional and oncologic outcomes of prostate gland ablation vs. standard of care therapies for localized prostate: A retrospective cohort study using the TriNetX database.

Diagnostic value of prostate magnetic resonance imaging in men with prostate-specific antigen levels ≥ 15 ng/mL for biopsy decision-making.

Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer.

Prevention of lymphoceles using peritoneal flaps during robotic-assisted radical prostatectomy with pelvic lymph node dissection: A systematic review and meta-analysis.

Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial.

A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population.

PSA and PSMA kinetics after PSMA-PET & MR guided prostate SBRT with focal boost: Results from the phase II PROBE trial.

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Persistent Poverty and Its Interaction With Race: Their Influence on Prostate Cancer-Specific Mortality.

Factors Associated With Risk Stratification and Overall Survival of Black South African Men With Non-Metastatic Prostate Cancer.

ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.

Cost-Effectiveness of PSMA PET/CT as Single Procedure for Diagnosis and Staging High-Grade Prostate Cancer: A Single Center Experience.

LUMBER: A feasible MRI-based 3D printed mould platform for ex vivo sampling of prostate cancer.

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Bench-to-Bedside Evaluation of Sulforaphane/BroccoMax® on Fatty Acid Synthesis in Prostate Cancer.

Multilevel associations between prostate cancer testing and socioeconomic position: a population-based register study from Stockholm, Sweden.

Beyond Chronologic Age: Frailty, Geriatric Assessment, and Personalized Care for Older Adults With Genitourinary Cancer.

Androgen Metabolism in Prostate Cancer: Recent Advances.

Upper Tract Tumors

Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma.

Over-expression of Paternally Expressed Gene 10 (PEG10) Is Associated With Poor Prognosis in Upper Tract Urothelial Carcinomas.

Testicular Cancer

Genomic landscape of pediatric germ cell tumors reveals oncogenic mutations and copy number alterations.

Risk of childhood and adolescent, and young adult cancer in offspring of men with testicular cancer: A Danish nationwide study.

Comparative Analysis of the Transcriptomic Response to Cisplatin in Drug-Sensitive and Drug-Resistant Testicular Germ Cell Tumors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC